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ABSTRACT 19 
The hepatitis E virus is a common cause of acute hepatitis. Contrary to hepatitis B and C, hepatitis E is 20 
mostly a mild infection, although it has a high mortality in pregnant women and can evolve to 21 
chronicity in immunocompromised patients. Ribavirin and pegylated interferon-α are the only 22 
available therapies, but both have side effects that are not acceptable for prophylaxis or treatment of 23 
mild infections. In addition, these drugs cannot be used for all patient types (e.g. in case of 24 
pregnancy, specific organ transplants or co-morbidities) and in resource-poor settings. Hence there is 25 
an urgent need for better antiviral treatments that are efficacious and safe, also during pregnancy. In 26 
this review, a concise introduction to the virus and disease is provided, followed by a discussion of 27 
the available assay systems and potential molecular targets (viral proteins and host factors) for the 28 
development of inhibitors of HEV replication. Finally, directions for future research are presented. 29 
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1. INTRODUCTION 32 
Hepatitis E virus (HEV) is a feco-orally transmitted pathogen and one of the most common causes of 33 
acute hepatitis worldwide. Although the virus was already identified in 1983 (Balayan et al., 1983), 34 
many of its epidemiological and clinical features are becoming clear just recently. HEV is responsible 35 
for both acute outbreaks in developing countries and sporadic cases worldwide and is more and 36 
more being recognized as a problem in the transplant setting (Kamar et al., 2008a; Pischke et al., 37 
2012). Although most infections are self-resolving, hepatitis E is characterized by a high mortality in 38 
pregnant women and can lead to chronic infections in immunocompromised patients. A vaccine has 39 
recently been approved for the Chinese, but not for other markets (Zhu et al., 2010). Current 40 
therapeutic options (i.e. ribavirin and interferon-α) have severe side effects and treatment failure has 41 
been reported. It may be important to have potent and safe inhibitors of HEV replication at hand to 42 
rapidly contain outbreaks and to treat immunodeficient patients. 43 
In this review, a general introduction to HEV is presented, followed by an overview of different 44 
potential antiviral targets and currently available methods for drug testing. Directions for developing 45 
antivirals against the HEV will be suggested. 46 
2. HEPATITIS E VIRUS 47 
a. Genome structure 48 
HEV has a capped positive-sense single-stranded RNA genome that comprises a 5’ untranslated 49 
region (UTR), open reading frames (ORF) 1 to 3 and a 3’ UTR followed by a polyA-tract (see figure 1). 50 
ORF1 encodes the non-structural proteins and contains methyltransferase, protease, macrodomain, 51 
helicase and RNA-dependent RNA polymerase (RdRp)-encoding sequences (Koonin et al., 1992). 52 
Between the protease and the macrodomain, a hypervariable region containing a proline-rich hinge 53 
was found (Smith et al., 2012). The overlapping ORFs 2 and 3 are translated from a single subgenomic 54 
RNA into the structural proteins (Graff et al., 2006). ORF2 encodes the 660-aa capsid protein that 55 
consists of a shell domain (S), a middle domain (M, also called P1) and a protruding domain (P, also 56 
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called P2) (Guu et al., 2009; Yamashita et al., 2009). The protein translated from ORF3 is 114 aa in 57 
length, is phosphorylated (Zafrullah et al., 1997) and unique to HEV and closely related viruses. 58 
b. Replication cycle 59 
Although understudied, the HEV replication cycle seems typical for a single-stranded RNA virus of 60 
positive polarity (see figure 2). The virus particle first binds to heparan sulphate proteoglycans 61 
(HSPGs) on the host cell membrane (Kalia et al., 2009), transfers to its (unknown) cellular membrane 62 
receptor(s) and the resulting complex is internalized through clathrin-mediated endocytosis (Kapur et 63 
al., 2012). Consequently, the capped viral genome is released from the virion during the uncoating 64 
process and directly translated by the host cell ribosomal machinery. The non-structural proteins 65 
thus generated allow for the replication of the viral genome (probably in specific viral replication 66 
complexes) and the production of subgenomic RNA that is translated into the structural proteins 67 
from ORF2 and ORF3. Full-length RNA progeny is assembled with ORF2 capsid protein into viral 68 
particles of 27 to 30 nm (Balayan et al., 1983) that are consequently released from the cell in a non-69 
lytic fashion. During release, HEV particles probably acquire a lipid bilayer (envelope) and associated 70 
ORF3 protein that are removed later by bile salts and enteric proteases respectively (Takahashi et al., 71 
2010; Yamada et al., 2009). 72 
c. Genetic diversity 73 
HEV is classified into the Hepevirus genus in the family of the Hepeviridae (ref ICTV). At least 4 74 
genotypes are currently recognized (Smith et al., 2013); genotypes 1 and 2 solely infect humans while 75 
genotypes 3 and 4 are zoonotic agents with their main reservoir in domestic pigs (Feagins et al., 76 
2007; Meng et al., 1997; Tamada et al., 2004). Two additional genotypes have been proposed for 77 
HEV isolates from Japanese wild boars (Smith et al., 2013). Several viruses that are more or less 78 
related to HEV have been isolated from different species, including chickens (avian HEV, (Haqshenas 79 
et al., 2001)), rabbits (Zhao et al., 2009), rats (Johne et al., 2010), bats (Drexler et al., 2012), ferrets 80 
(Raj et al., 2012) and trout (Batts et al., 2011) (figure 3). The exact classification of these viruses 81 
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remains to be determined (Smith et al., 2013) and future discovery of additional hepeviruses seems 82 
likely. 83 
3. HEPATITIS E 84 
a. Epidemiology of disease 85 
HEV genotypes 1 and 2 only infect humans and are endemic in many developing regions where they 86 
tend to cause large-scale water-borne outbreaks (Corwin et al., 1996; Naik et al., 1992). Genotype 1 87 
is mainly found in Asia and Africa (Sugitani et al., 2009; Teshale et al., 2010), while genotype 2 has 88 
been isolated from Mexico and Africa, but seems less common (Maila et al., 2004; Velázquez et al., 89 
1990) (see figure 4). It is estimated that infections with these genotypes result in 70,000 deaths 90 
annually (Rein et al., 2012). Genotypes 3 and 4 on the other hand are zoonotic agents with their main 91 
reservoir in domestic pigs (Colson et al., 2010; Li et al., 2005; Takahashi et al., 2004). Genotype 3 has 92 
a worldwide distribution, while genotype 4 is mostly found in Asia (Miyashita et al., 2012; Wang et 93 
al., 2012). However, genotype 4 has also been isolated from European pigs and patients recently 94 
(Hakze-van der Honing et al., 2011; Jeblaoui et al., 2013). Genotype 3 and 4 infections often result 95 
from consumption of undercooked pig or deer meat and may thus cause sporadic cases of hepatitis 96 
E. Although exact epidemiological data are missing, these infections seem a lot more common than 97 
initially thought (Dalton et al., 2008; Ijaz et al., 2009; Versluis et al., 2013). 98 
b. Clinical syndromes 99 
Acute hepatitis E is characterized by jaundice, fatigue, gastrointestinal discomfort etc. and is clinically 100 
indistinguishable from for instance hepatitis A (Khuroo, 1980), although many infections remain 101 
asymptomatic. Most cases of hepatitis E resolve spontaneously, but in some patients the infection 102 
may progress to fulminant hepatitis. Overall mortality rates are estimated between 0.5 and 4% (e.g. 103 
(Khuroo, 1980; Teshale et al., 2010)).  104 
One particularly intriguing characteristic is that hepatitis E is often lethal in pregnant women with 105 
mortality rates of up to 20-25% (Khuroo et al., 1981; Tsega et al., 1993), although this has only been 106 
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observed for genotype 1 infections. Increased frequencies of obstetric complications and stillbirths 107 
have also been reported (Patra et al., 2007). The underlying mechanisms of this phenomenon 108 
(hormonal, immunological, genetical factors, etc.) are unclear to date. 109 
A more recent finding is that HEV can establish chronic infections in immunocompromised subjects 110 
such as transplant and HIV-infected patients (Colson et al., 2009; Dalton et al., 2009; Kamar et al., 111 
2008b). This has only been reported for genotype 3 thus far. Such chronic infections are rarely 112 
symptomatic and are sometimes mistaken for drug-induced liver injury (Davern et al., 2011). Chronic 113 
hepatitis E may lead to cirrhosis in 10% of patients (Kamar et al., 2011) and can ultimately result in 114 
death. 115 
Occasional extrahepatic manifestations have also been reported; these are mostly neurological 116 
complications such as Guillain-Barré syndrome and neuralgic amyotrophy (Fong and Illahi, 2009; 117 
Kamar et al., 2010b; Sood et al., 2000) or nefrological manifestations such as glomerulonephritis 118 
(Kamar et al., 2012). 119 
As evident from the discussion above, hepatitis E is profoundly different from the well-known disease 120 
courses of hepatitis B and C. While a considerable portion of patients infected with the hepatitis B 121 
virus (HBV) and especially the hepatitis C virus (HCV) evolves to chronicity, spontaneous recovery is 122 
the rule for hepatitis E where chronic disease has thus far only been reported in 123 
immunocompromised patients. The high rate of mortality in pregnant women is also unique to 124 
hepatitis E and no similar phenomena have been reported for hepatitis A, B or C. 125 
c. Diagnostic methods 126 
The most frequently used tests for diagnosing hepatitis E are detection of IgM and IgG antibodies by 127 
enzyme-linked immunosorbent assays (ELISA) and detection of viral RNA by (quantitative) reverse 128 
transcription PCR (RT-PCR). Presence of IgM antibodies indicates a recent infection, while IgG 129 
antibodies appear later and persist afterwards, at least for some time, indicating a past exposure. 130 
The current ELISAs suffer from large variability between assays (Bendall et al., 2010; Drobeniuc et al., 131 
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2010; Mast et al., 1998) and therefore require urgent optimization and validation. Acute infection is 132 
usually confirmed by (quantitative) RT-PCR (e.g. (Jothikumar et al., 2006)), although these assays 133 
should be standardized as well to increase reliability. 134 
Since the incubation and symptomatic periods for acute hepatitis E are only a few weeks, the 135 
successful use of antiviral drugs for acute cases of hepatitis E would depend on the availability of a 136 
rapid and inexpensive diagnostic test. Such test should also be easy to employ in resource-poor 137 
settings.  138 
4. CURRENT CONTROL STRATEGIES 139 
a. Vaccines 140 
Vaccination would be an effective strategy to prevent HEV infection. Recently, such a HEV vaccine 141 
based on a recombinant truncated capsid protein was approved in China (Hecolin®, (Zhu et al., 142 
2010)). It remains unclear whether the manufacturer intends to obtain market approval in other 143 
countries as well. Another recombinant vaccine successfully completed phase 2 clinical trials in Nepal 144 
(Shrestha et al., 2007), but further development was halted. Such vaccines may be useful as a 145 
prophylactic measure in high-risk patients such as immunocompromised patients and pregnant 146 
women. This would require specific clinical trials to demonstrate protective efficacy in these 147 
populations; to the best of our knowledge, such studies have not yet been reported for Hecolin®. 148 
However, the organization of large-scale vaccination campaigns against HEV may not be particularly 149 
cost-effective given the mostly benign course of infection in developing countries and the relatively 150 
low incidence in the developed world. 151 
b. Other prophylactic measures 152 
Since HEV is transmitted feco-orally, sanitary measures are probably the most effective strategy 153 
available to prevent viral spread. This is especially the case for genotypes 1 and 2 that often occur in 154 
large water-borne outbreaks. Availability of clean drinking water and proper disposal of waste water 155 
would be effective control strategies. Genotypes 3 and 4 are mostly spread through contaminated 156 
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food stuffs, such as the infamous French figatellu sausage made from uncooked pig liver (Berto et al., 157 
2013a; Colson et al., 2010). Thorough heating effectively kills the virus and prevents infection 158 
(Feagins et al., 2008a). Although ineffectively, HEV can also be transmitted via blood transfusion 159 
(Boxall et al., 2006; Colson et al., 2007), suggesting that screening of donor blood may be warranted. 160 
In addition, vertical transmission of HEV has been reported (Khuroo et al., 1995), indicating that extra 161 
caution is required in pregnant women. 162 
5. WHY DO WE NEED ANTIVIRAL DRUGS AGAINST HEPATITIS E VIRUS? 163 
a. Current standard of care 164 
Chronic HEV infections in transplant patients can occasionally be resolved by decreasing 165 
immunosuppresion, leading to spontaneous clearance in about 30% of the patients (Kamar et al., 166 
2011). When this approach is unsuccessful and for other types of patients, there are generally 2 167 
possibilities: the use of pegylated interferon-alpha (PEG-IFNα) or ribavirin. PEG-IFNα has been used 168 
successfully in liver transplant, kidney transplant and leukemia patients with chronic hepatitis E (Alric 169 
et al., 2010; Haagsma et al., 2010; Kamar et al., 2010a, 2010c). However, ribavirin seems to be the 170 
drug of choice in most cases with successful treatments being reported for multiple types of 171 
transplant patients (Kamar et al., 2010d; Mallet et al., 2010; Pischke et al., 2013, 2012), but also for 172 
HIV and leukemia patients with chronic hepatitis E (Giordani et al., 2013; Neukam et al., 2013). Acute 173 
hepatitis E seems to respond to ribavirin treatment as well (Gerolami et al., 2011; Pischke et al., 174 
2013). In addition, the anti-HEV activity of both drugs has been confirmed in vitro (Debing et al., 175 
2013a). Nevertheless, they need to be administered for at least 3 months and are known for their 176 
severe adverse effects. For PEG-IFNα for instance, this includes influenza-like symptoms and 177 
neuropsychiatric side effects (Manns et al., 2006). Ribavirin on the other hand may induce severe 178 
anemia necessitating dose reductions (Kamar et al., 2010d; Pischke et al., 2012). These reductions 179 
may in turn lead to treatment failure (Pischke et al., 2013). One may deem such severe side effects 180 
acceptable in light of the severity of chronic hepatitis E (as is the case for chronic hepatitis C as well), 181 
but this is certainly not true when these drugs would be used for prophylaxis or to treat mild 182 
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infections. In addition, both ribavirin and PEG-IFNα are contra-indicated in pregnant women and 183 
other specific patient populations, leaving no available treatment options for these people. Also 184 
when considering acute infections during large outbreaks in developing countries, PEG-IFNα is not an 185 
option due to the fact that parenteral administration is needed and the required follow-up of 186 
hematological parameters during ribavirin treatment is difficult to implement in such settings. 187 
b. Future therapy for hepatitis E 188 
For the reasons stated above, safe and effective treatments for hepatitis E are urgently required. In 189 
case of acute infections, antiviral drugs would be useful to shorten the period of illness and prevent 190 
progression to fulminant hepatic failure. Such application would require rapid diagnosis of hepatitis E 191 
(see also section 3.c.). Another possibility would be to use antivirals to halt viral spread during 192 
epidemics and outbreaks. The fact that these outbreaks occur rather often in refugee camps (e.g. 193 
(Ahmed et al., 2013; Centers for Disease Control and Prevention (CDC), 2013)) may represent an 194 
opportunity for clinical trials testing the prophylactic potential of HEV inhibitors if such studies would 195 
be appropriate from an ethical point-of-view. 196 
In pregnant women, such drugs could be life-saving for both mother and child, on the condition that 197 
they are devoid of teratogenic and significant adverse effects. Ideally, these women should be 198 
screened regularly with a rapid and sensitive HEV test and treated as soon as possible. This may be 199 
difficult to implement in developing countries where genotype 1 is endemic, so an approved HEV 200 
inhibitor should be sufficiently potent to arrest an established (fulminant) infection. Modulation of 201 
the hormonal system may be another interesting therapeutic option (see suggestions in section 7.f.), 202 
although the development of such strategy would require more detailed insights into disease 203 
pathogenesis. 204 
For chronically infected patients, rapid clearance of HEV is required before irreversible progression to 205 
cirrhosis has occurred. Ideally, these drugs should be applicable in a diverse range of 206 
immunocompromised patients without overt toxicity. Since ribavirin treatment has a rather good 207 
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efficacy in chronically HEV-infected patients, a combination regimen with another HEV-inhibitor 208 
could be envisaged (as is currently being explored for HCV: ribavirin + direct-acting antiviral(s), e.g. 209 
(Osinusi et al., 2013; Zeuzem et al., 2013)). This may allow decreasing the ribavirin dosage, thus 210 
reducing and hopefully avoiding anemia and other side effects. In addition, we observed a slight 211 
synergistic effect in vitro for the combination of ribavirin and interferon-α (Debing et al., 2013a), 212 
suggesting that such a combination regimen may be worth considering in the clinical setting. 213 
Successful combination therapy has already been reported for a chronically HEV-infected HIV patient 214 
(Dalton et al., 2011b). 215 
Developing antiviral drugs for the treatment of HEV infections will commercially not be as rewarding 216 
as for instance the development of HCV inhibitors (Debing et al., 2013b). Therefore, it appears 217 
opportune to consider other strategies than the classical discovery-development of completely new 218 
chemical entities as well, for instance off-label use of drugs with robust anti-HEV activity that are 219 
registered for unrelated indications when such molecules would be identified. 220 
6. CURRENTLY AVAILABLE METHODS FOR DRUG TESTING 221 
a. In vitro testing 222 
Efficient cell culture systems for HEV have only recently become available. The Okamoto research 223 
group reported on both genotype 3 and 4 strains that replicate in PLC/PRF/5 (hepatoma) and/or 224 
A549 (lung adenocarcinoma) cell lines (Takahashi et al., 2010; Tanaka et al., 2009, 2007). The 225 
PLC/PRF/5 cells were also employed in a 3D cell culture system for HEV (Berto et al., 2013b). On the 226 
other hand, the NIH research group of Emerson derived a passage 6 virus of the Kernow-C1 strain 227 
that replicates in Huh7 and especially HepG2/C3A hepatoma cells (Shukla et al., 2012, 2011). This 228 
strain is derived from a chronically infected patient and contains an inserted human ribosomal S17 229 
RNA fragment in the hypervariable region (Shukla et al., 2011). Detailed analyses indicated that this 230 
fragment and several additional mutations contributed to the improved in vitro replication. Although 231 
the replication capacity of this strain is sufficient for virus yield assays (e.g. (Debing et al., 2013a)), 232 
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overall growth kinetics are still rather slow. No cytopathic effect (CPE) has been described for any of 233 
these HEV strains, precluding the use of standard virology techniques such as CPE reduction assays 234 
and plaque assays. In addition, genotype 1 replicates only poorly in cell culture (Nguyen et al., 2013) 235 
while it probably accounts for most of the human infections worldwide. 236 
Several replicon constructs have also been established in which the 5’ part of the structural proteins 237 
is replaced by a GFP, neomycin resistance or luciferase gene (Graff et al., 2006; Shukla et al., 2012). 238 
The Kernow-C1 p6/luc reporter replicon proved especially useful in our hands as transient 239 
transfection into Huh7 cells allows for a 3-day antiviral assay to be performed (Debing et al., 2013a). 240 
For large-scale cell-based screenings with such replicons, a selectable reporter replicon would be 241 
highly convenient. 242 
Another possible strategy to identify novel inhibitors of HEV replication is to use a surrogate virus. 243 
We recently reported that the cutthroat trout virus (CTV) may serve as such a surrogate (Debing et 244 
al., 2013c). CTV was isolated in 1988 from spawning trout in the western USA (Hedrick et al., 1991) 245 
and recent studies revealed that the virus belongs to its own genus in the Hepeviridae family (Smith 246 
et al., 2013). It has a remarkable similarity to HEV, especially when considering the helicase and 247 
polymerase sequences (Batts et al., 2011; Debing et al., 2013c). CTV replicates readily in cell culture 248 
allowing for RT-qPCR-based virus yield assays to be performed (Debing et al., 2013c). In addition, its 249 
in vitro replication kinetics can be further improved through repeated passaging (our unpublished 250 
results). In addition, CTV is a cytopathic virus. The CPE induced in CHSE-214 cells is rather limited, but 251 
we observed that nearly complete CPE can be attained in other piscine cell lines (our unpublished 252 
results). The avian HEV has also been successfully employed as a surrogate model (e.g. (Kenney et al., 253 
2012; Pudupakam et al., 2011)). 254 
In conclusion, recent developments have considerably expanded the number of assays and tools 255 
available for HEV antiviral studies. However, the possibilities are still rather limited and the field 256 
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would benefit from for instance HEV strains with improved replication kinetics, enzymatic assays for 257 
the different non-structural proteins and selectable reporter replicons. 258 
b. Evaluation in laboratory animals 259 
An ideal animal model for HEV would be a small inexpensive animal (preferably rodent) that can be 260 
infected with human HEV or at least a closely related virus and that develops acute hepatitis with a 261 
clear increase in liver markers and with high viral titers. Mortality is not required, although a lethal 262 
phenotype is highly useful for antiviral drug testing. An animal model that mimics the hormone-263 
dependent effects observed in pregnant women would be a plus. 264 
Several animal models are available for in vivo HEV studies (see table 1 for an overview), but they all 265 
have certain limitations. For instance, chicken and trout can be used as experimental animal models 266 
when infected with avian HEV and CTV respectively (Billam et al., 2005; Hedrick et al., 1994). Since 267 
both viruses are only surrogates for human HEV, further validation of experimental results would be 268 
required in another model. Genuine HEV infections can be performed in pigs ((Feagins et al., 2008b; 269 
Halbur et al., 2001; Sanford et al., 2011) and non-human primates such as macaques and 270 
chimpanzees (Emerson et al., 2001; Meng et al., 1998; Purcell et al., 2003; Yu et al., 2010). , However, 271 
ethical concerns as well as practical issues may make such studies complicated. Rodents may present 272 
a more accessible model organism. For instance, laboratory rats can be experimentally infected with 273 
rat HEV, but contradicting reports have been published for the human HEV genotypes (Li et al., 274 
2013a, 2013b; Purcell et al., 2011; Zhu et al., 2013). Successful infection of Balb/c nude but not 275 
C57BL/6 mice with HEV was reported (Huang et al., 2009; Li et al., 2008), while rabbits can be 276 
infected with rabbit HEV and certain genotype 4 strains (Cheng et al., 2012). Finally, infection of 277 
Mongolian gerbils with genotype 4 has also been reported (Li et al., 2009). Due to the large variability 278 
between published results, a robust model that has been evaluated by multiple laboratories has not 279 
yet been reported. In addition, none of these models resulted in a lethal phenotype. For the 280 
predominant genotype 1 HEV, primates are even the only available model at this time. Promising 281 
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strategies towards a robust animal model may be infection of immunedeficient rats or mice with rat 282 
HEV, discovery studies for a murine HEV species, HEV infection of mice with chimeric human or 283 
porcine livers (Meuleman et al., 2005) or establishment of transgenic mice with a human HEV 284 
receptor (when identified), as was done successfully for poliovirus (Ren et al., 1990) and HCV (Dorner 285 
et al., 2011). 286 
c. Clinical trials 287 
When a HEV inhibitor would be shown to be successful in a (surrogate) animal model and would have 288 
an excellent safety and pharmacokinetic profile, clinical studies would be the next stage in 289 
development. For these studies, one could consider treating chronically infected patients, possibly in 290 
a combination regimen with ribavirin. However, these patients may have multiple co-morbidities and 291 
there could be confounding factors such as concomitant drug use leading to drug-drug interactions. 292 
Since hepatitis E has a rather long incubation period and clinical symptoms are often apparent for 293 
several weeks, clinical studies could possibly be performed in an outbreak setting as well; in this way, 294 
both prophylactic and therapeutic efficacy may be assessed. 295 
7. POTENTIAL DRUG TARGETS 296 
Below we present a selection of viral and host proteins may be attractive targets for antiviral therapy 297 
(see also table 2). 298 
a. Inhibitors of HEV entry 299 
The entry of a virus particle into the host cell is a multi-step process that involves attachment of the 300 
virus to its receptor on the cellular membrane, internalization of the virion-receptor complex and 301 
subsequent uncoating of the viral capsid releasing the RNA genome into the cytoplasm. The 302 
functional HEV receptor is still unknown to date, although there are indications that genotype 1 may 303 
use a different receptor(s) than genotype 3 (Nguyen et al., 2013). It was also found that HEV attaches 304 
to HSPGs, more specifically to 6-O-sulfated syndecan-1, which may account for its liver tropism (Kalia 305 
et al., 2009). It is hypothesized that HSPGs act as a highly abundant initial attachment receptor that 306 
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binds HEV with relatively low affinity. In a second step, the virion probably transfers to a high-affinity 307 
functional receptor and the resulting complex is internalized. Structure determination of a HEV-like 308 
particle combined with mutation and cell binding studies have identified a receptor binding site on 309 
top of the P2 dimer that protrudes from the 2-fold axis of symmetry (Yamashita et al., 2009). 310 
Interestingly, this site is homologous to the norovirus receptor-binding site that attaches to histo-311 
blood group trisaccharides (Guu et al., 2009). In addition, another sialic acid-binding site was found in 312 
the P1 region of the capsid protein (Guu et al., 2009). 313 
Despite the limited information that is available on HEV attachment and entry, several potentially 314 
interesting antiviral strategies can be derived from these data. First, the homology between the 315 
putative HEV and norovirus receptor-binding sites suggests that norovirus attachment inhibitors 316 
could possibly be interesting leads for further development into anti-HEV drugs. No confirmed 317 
norovirus entry inhibitors have been described to date, but two potentially interesting prototype 318 
molecules were designed through NMR binding studies (Rademacher et al., 2011) and in a similar 319 
way, citrate was found to compete with histo-blood group saccharides for norovirus binding 320 
(Hansman et al., 2012), suggesting a promising role for glycomimetics. A second and possibly 321 
overlapping approach is to search for inhibitors of HEV attachment to HSPGs. Heparan sulphate and 322 
related molecules inhibit the attachment of multiple viruses, both in vitro and in vivo (e.g. (Ali et al., 323 
2012; Bugatti et al., 2007; Lee et al., 2006)). However, the clinical applicability of such molecules 324 
remains questionable and would require complete abolishment of any anticoagulative properties. 325 
Pentosan polysulphate is such an oligosaccharide derivative that is approved and marketed for pain 326 
relief in interstitial cystitis (Davis et al., 2008). Given that this drug inhibits entry of multiple viruses 327 
(Baba et al., 1988; García-Villalón and Gil-Fernández, 1991), it may be worthwhile to test it as a 328 
therapeutic option for hepatitis E, although it still has some anticoagulant properties (Scully et al., 329 
1983). Thirdly, it has been shown that a truncated ORF2 protein is capable of preventing HEV 330 
infection in vitro (He et al., 2008). Through further truncation of this protein or otherwise mimicking 331 
the receptor-binding region of HEV, it would theoretically be possible to prevent virions from binding 332 
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to their cellular receptor. To illustrate the feasibility of such an approach, we refer to Myrcludex-B 333 
which is a lipopeptide derived from the HBV envelope protein and efficiently inhibits HBV entry in 334 
vitro and in vivo (Volz et al., 2013). 335 
The strategies outlined above illustrate that the lacking of an identified receptor is an important 336 
hurdle for the identification and study of attachment, entry and uncoating inhibitors for HEV. Now 337 
that efficient cell culture systems are available (e.g. (Shukla et al., 2012)), this hiatus can and should 338 
be addressed. 339 
b. RNA-dependent RNA polymerase inhibitors 340 
Following release of the viral RNA in the cytoplasm and initial translation, the RNA genome is 341 
replicated by an RNA-dependent RNA polymerase. Sequence alignments predicted an RdRp-encoding 342 
sequence at the 3’ end of ORF1 (see figure 1, (Koonin et al., 1992)) that belongs to the alphavirus-343 
supergroup of RdRp’s (Koonin, 1991). The polymerase activity was later confirmed by detection of 344 
newly synthesized negative-sense viral RNA in vitro (Agrawal et al., 2001; Rehman et al., 2008). The 345 
RdRp interacts with stem loops in the 3’ end of the viral genome and with the polyA-tail (Agrawal et 346 
al., 2001) and co-localizes with the endoplasmatic reticulum (Rehman et al., 2008). However, further 347 
details about the HEV RdRp structure and function are missing. 348 
As evidenced by the success of nucleoside and nucleotide inhibitors of HIV and herpesviruses, viral 349 
polymerases are attractive targets for antiviral therapy. Also the RdRp of RNA viruses has been 350 
targeted successfully by such molecules, consider for instance the nucleoside analogues that were 351 
developed against HCV, e.g. sofosbuvir is highly active, safe and has a high barrier to resistance. 352 
Sofosbuvir has successfully completed phase 3 clinical trials (Lawitz et al., 2013) and may receive 353 
market approval in the near future. 2’-C-methylcytidine (2’CMC) is a related molecule and was the 354 
first nucleoside analogue that entered clinical studies for the treatment of HCV infections. It has been 355 
shown to in vitro inhibit the replication of a number of other positive-sense single-stranded RNA 356 
viruses (Julander et al., 2010; Rocha-Pereira et al., 2013). However, neither 2’CMC nor a number of 357 
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its analogues exhibited significant activity in the transient HEV replicon assay (as described in (Debing 358 
et al., 2013a), unpublished results). Also only moderate antiviral activity of 2’CMC was observed 359 
against CTV (Debing et al., 2013c). Despite these negative results, other nucleos(t)ide analogues may 360 
possibly be interesting inhibitors of HEV replication. Moreover, research efforts could be directed 361 
towards developing an RdRp inhibitor that targets both HEV and the distantly related alphavirus 362 
family. Such a broad-spectrum inhibitor would provide a much-needed treatment option for multiple 363 
infections by neglected viruses such as the Chikungunya virus, Sindbis virus and the equine 364 
encephalitis viruses. Elucidation of the HEV RdRp crystal structure and development of a convenient 365 
enzymatic assay would allow to jumpstart this specific domain of HEV antiviral research. 366 
c. Methyltransferase inhibitors 367 
The HEV genome has a 5’ cap structure which is a crucial requirement for infectivity (Emerson et al., 368 
2001). Capping is a multistep process involving hydrolysis of the γ-phosphate from the terminal 369 
nucleotide, subsequent conjugation to GMP resulting in a 5’-ppp-5’ triphosphate bond and finally 370 
methylation of the newly added guanosine. The 5’ proportion of the ORF1 sequence was predicted to 371 
encode a viral methyltransferase (Koonin et al., 1992) and indeed, the expressed protein displays 372 
guanyltransferase and guanine-7-methyltransferase activities (Magden et al., 2001). The missing RNA 373 
triphosphatase function may be fulfilled by the HEV helicase (Karpe and Lole, 2010a). 374 
Since HEV is heavily dependent on the capping of its RNA genome for infectivity, the viral 375 
methyltransferase seems an ideal target for antiviral therapy, all the more since these enzymatic 376 
activities are virus-specific (Magden et al., 2001) and thus may allow for development of selective 377 
inhibitors. Successful targeting of viral methyltransferases has been described for instance for 378 
dengue virus (Barral et al., 2013) and West Nile virus (Chen et al., 2013). Moreover, a highly efficient 379 
inhibitor of Chikungunya virus replication that selects for resistance mutations in nsP1 (viral 380 
methyltransferase) was recently identified in our laboratory (unpublished results; Delang L., Leyssen 381 
P. & Neyts J.); indicating that inhibition of this transferase may be a valuable strategy to inhibit the 382 
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replication of RNA viruses, including HEV. Solving the crystal structure and development of robust 383 
enzymatic assays would be significant advances. 384 
d. Helicase inhibitors 385 
RNA viruses require the RNA-unwinding activity of a virally encoded helicase enzyme for replication; 386 
the energy needed for this process is provided by the hydrolysis of NTPs (Kwong et al., 2005). As for 387 
the RdRp and methyltransferase, the NTPase and RNA unwinding activities of the predicted HEV 388 
helicase domain have been confirmed in vitro (Karpe and Lole, 2010b). This helicase belongs to the 389 
5’-to-3’ unwinding SF-1 helicase superfamily, which also comprises the alphavirus and coronavirus 390 
(CoV) helicases. Potent inhibitors have been identified for the SARS-CoV nsP13 helicase (Adedeji et 391 
al., 2012; Tanner et al., 2005), suggesting that it may also be possible to develop inhibitors of the HEV 392 
helicase. An important caveat is that such inhibitors need to be highly specific for viral helicases 393 
without affecting host helicase activity to avoid toxicity. Examples from the herpesvirus field 394 
(helicase-primase inhibitors such as letermovir which has successfully finished phase 2 clinical studies 395 
(Marschall et al., 2012)) show that such selectivity can be attained. 396 
e. Targeting other viral proteins 397 
Besides the above mentioned enzymes, the HEV genome encodes several other proteins of which the 398 
function and significance have not been elucidated completely, like the macro domain, the viral 399 
protease and the ORF3 protein. Given that more information would become available, they may 400 
constitute suitable targets for antiviral therapy. 401 
The macrodomain, formerly known as the X-domain, is located just upstream of the helicase gene 402 
(figure 1, (Koonin et al., 1992)). Its name is derived from the homologous non-histone domain of the 403 
macroH2A histone (Egloff et al., 2006). The exact function of the HEV macrodomain is unclear, 404 
although it strongly binds poly(ADP-ribose) (Egloff et al., 2006), an important post-translational 405 
protein modification involved in cell survival and apoptosis, among other functions (Schreiber et al., 406 
2006). Since it has been suggested that the biological function of viral macrodomains may be 407 
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unrelated to that of their human homologs (Neuvonen and Ahola, 2009), they could represent 408 
attractive targets for inhibition. However, this would require a more profound understanding of the 409 
function and activity of this domain. 410 
Secondly, a papain-like cysteine protease domain has been predicted in the HEV genome sequence 411 
(Koonin et al., 1992), but it remains unclear whether this protease is fully functional. Consequently, 412 
one of the enigmas of HEV molecular biology is whether ORF1 is processed into discrete functional 413 
units or not: several publications reported processing of ORF1 to some extent (Panda et al., 2000; 414 
Parvez, 2013; Ropp et al., 2000; Sehgal et al., 2006), while others found no processing whatsoever 415 
(Ansari et al., 2000; Perttilä et al., 2013; Suppiah et al., 2011). On the other hand, deubiquitination 416 
activity has been reported for the methyltransferase-protease fusion domain which may be involved 417 
in combating cellular antiviral responses (Karpe and Lole, 2011) and a recent mutational study 418 
suggested a glycine-triad as the protease substrate sequence (Parvez, 2013). Although viral proteases 419 
in general are interesting targets for antiviral therapy (as exemplified in the fields of HIV and HCV), 420 
more insight into the activity, function and structure of the HEV protease would be essential before 421 
focusing on protease inhibitors. 422 
ORF3 encodes a 114aa phosphoprotein (Graff et al., 2006) that is exclusively found in hepeviruses. 423 
ORF3 protein is dispensable for in vitro infection of cultured cells (Emerson et al., 2006), but required 424 
for infection and seroconversion of rhesus macaques (Graff et al., 2005). A number of functions have 425 
been proposed and several binding partners have been identified (Holla et al., 2013; Ratra et al., 426 
2008), but in general, ORF3 protein seems to optimize the host cell for HEV replication by increasing 427 
cell survival (Chandra et al., 2010, 2008; Moin et al., 2007) and suppressing interferon-α signaling 428 
(Dong et al., 2012). In addition, ORF3 protein has been implicated in virion egress (Yamada et al., 429 
2009) and disruption of blood coagulation (Geng et al., 2013). It should be noted that most of these 430 
results have been obtained in artificial systems, i.e. overexpression of ORF3 protein in cultured cells 431 
instead of genuine infection with HEV. In order to be targeted for antiviral development, more 432 
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insight into the ORF3 structure and function is required. Since the protein has multiple cellular 433 
binding partners, it may be interesting to look for inhibitors of these protein-protein interactions (see 434 
also section 7.f.). Such an approach may yield very specific inhibitors of HEV replication with low 435 
toxicity and a high barrier to resistance, especially given the overlap with ORF2 which is expected to 436 
substantially limit the number of viable mutations. The feasibility of identifying protein-protein 437 
interaction inhibitors as antiviral molecules was proven for the interaction between LEDGF/p75 and 438 
the HIV integrase for instance (Christ et al., 2010). 439 
f. Host factors 440 
Since many direct-acting antiviral agents are prone to the emergence and selection of resistant 441 
viruses, there is an increasing interest in targeting host factors that are co-opted by viruses for their 442 
own replication. Such host factor-targeting antivirals should have an increased barrier to resistance 443 
and may potentially have broad-spectrum activity. Multiple binding partners have been identified for 444 
HEV structural and non-structural proteins. The functional significance of many of these interactions 445 
remains unclear to date, but some of the host factors may be well-suited for antiviral targeting. Here, 446 
we discuss a few host factors that we believe have the most potential at being drugable. 447 
First, tumor susceptibility gene 101 (Tsg101) is a central mediator in the endosomal protein sorting 448 
pathway (Surjit et al., 2006). HEV ORF3 protein has a PSAP-motif through which it associates with 449 
Tsg101, thus increasing secretion of the immunosuppressive α1-microglobulin and locally 450 
suppressing the host immune response (Surjit et al., 2006). In addition, Tsg101 is required for virion 451 
release by interacting with the ORF3 protein PSAP-motif (Kenney et al., 2012; Nagashima et al., 452 
2011a, 2011b). The involvement of Tsg101 in virion release is not limited to HEV; it was also found to 453 
be essential for HIV and Ebola virus budding (Garrus et al., 2001; Martin-Serrano et al., 2001) and is 454 
being explored as a target for antiviral therapy (Chen et al., 2010). For instance, cyclic peptides 455 
blocking the interaction between Tsg101 and the PTAP motif of the HIV Gag-protein were found to 456 
block HIV budding (Tavassoli et al., 2008). Moreover, Tsg101 is expressed on the cell membrane 457 
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during both HIV and influenza virus infection and targeting by antibodies blocks virus production 458 
(Bonavia et al., 2010; Diaz et al., 2010). Similar questions can be posed for HEV: does HEV induce 459 
expression of Tsg101 at the cell membrane? Can the interaction between Tsg101 and ORF3 be 460 
blocked with a small molecule or (cyclic) peptide? Potentially, antiviral research on HEV could piggy-461 
back on the ongoing efforts for HIV and influenza virus and thus advance rapidly. 462 
Another interesting finding is that the proteasome inhibitor MG132 inhibits HEV replication, 463 
indicating that HEV likely requires an active ubiquitin-proteasome system for infection (Karpe and 464 
Meng, 2012). Similar findings have been reported for influenza virus (Haasbach et al., 2011), HIV 465 
(Schubert et al., 2000) and vaccinia virus (Satheshkumar et al., 2009). This suggests that targeting the 466 
proteasome system may be an interesting strategy for identifying broad-spectrum antiviral drugs. 467 
Proteasome inhibitors such as bortezomib and carfilzomib are currently being used in the treatment 468 
of multiple myeloma, based on the increased susceptibility of cancer cells compared to non-469 
malignant cells (Hideshima et al., 2001). However, it is unknown whether such a selectivity can also 470 
be attained for virus-infected cells versus healthy cells to avoid severe side effects. 471 
A similar analysis may apply to heat shock protein 90 (hsp90) as a cellular target for anti-HEV drugs 472 
and antiviral therapy in general. Hsp90 is required for intracellular trafficking of HEV particles and 473 
inhibition of hsp90 with geldanamycin blocks HEV infection (Zheng et al., 2010). Many viruses 474 
depend on hsp90 and their replication can be blocked by hsp90 inhibitors (Basha et al., 2005; Geller 475 
et al., 2013; Sun et al., 2013). Such inhibitors are currently being developed as anticancer therapies 476 
((Jhaveri and Modi, 2012) for an overview), but the question remains if sufficient selectivity can be 477 
attained for safe antiviral therapy. An alternative strategy may be to specifically inhibit the protein-478 
protein interaction between the HEV capsid and hsp90, thus leaving hsp90 enzymatic activity 479 
undisturbed. 480 
Finally, there are multiple indications that HEV replication may be influenced by sex hormones. First, 481 
mortality increases dramatically in pregnant women infected with genotype 1 (up to 25%, (Khuroo et 482 
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al., 1981; Tsega et al., 1993)). The underlying mechanism is still unclear, but it is known that low 483 
progesterone receptor mRNA levels and mutations in the progesterone receptor gene (PROGINS) are 484 
associated with poor pregnancy outcome (fulminant hepatic failure, fetal and maternal death) during 485 
HEV infection (Bose et al., 2011). On the other hand, autochthonous HEV infections in developed 486 
countries seem to primarily affect males over 50 (Dalton et al., 2011a; Davern et al., 2011; Mansuy et 487 
al., 2009). We reported that the replication of the CTV, a HEV surrogate virus, can be directly 488 
influenced by different concentrations of progesterone, testosterone and 17β-estradiol (Debing et 489 
al., 2013c), suggesting the possibility of a similar phenomenon in HEV infection. Several potential 490 
strategies can be derived from the limited information that is available. Since decreased 491 
progesterone receptor activity is associated with poor pregnancy outcome in hepatitis E (Bose et al., 492 
2011) and high concentrations of progesterone inhibit CTV replication (Debing et al., 2013c), one may 493 
consider progesterone supplementation in pregnant women with hepatitis E. Such supplementation 494 
has been approved by the FDA for the prevention of preterm birth (Norwitz and Caughey, 2011). 495 
Similarly, testosterone levels decrease with age and low testosterone concentrations facilitate CTV 496 
replication (Debing et al., 2013c), suggesting that testosterone supplementation may be beneficial in 497 
elderly man (chronically) infected with HEV. A third possibility may be the use of selective estrogen 498 
receptor modulators (SERMs), such as tamoxifen and raloxifene. SERMs were found to inhibit HCV 499 
replication in vitro (Murakami et al., 2013; Watashi et al., 2007) and raloxifene improved the efficacy 500 
of pegylated interferon + ribavirin in menopausal women chronically infected with HCV (Furusyo et 501 
al., 2012). It would be interesting to look into the effects of SERMs on HEV or CTV replication as they 502 
may represent another possible treatment option for hepatitis E (but not during pregnancy). To fully 503 
explore the potential treatment of hepatitis E through modulation of the hormonal system, a robust 504 
animal model displaying hormone-dependent virus replication would be much appreciated. 505 
8. DIRECTIONS FOR FUTURE RESEARCH 506 
Antiviral drugs for the treatment of hepatitis E are required for both acute and chronic infections. 507 
Such drugs should have an increased potency, efficacy and safety compared to the currently used 508 
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ribavirin and PEG-IFNα, thus allowing for prophylactic use, containment of outbreaks and preferably 509 
treatment of pregnant women and other high-risk patients as well. It would also be interesting to 510 
further characterize the mechanism of action of ribavirin and PEG-IFNα in hepatitis E. As evident 511 
from the discussion above, HEV is an understudied pathogen and most of the suggested antiviral 512 
strategies require a more elaborate fundamental knowledge of the molecular virology. In addition, 513 
better model systems should be developed, both in vitro and in vivo, for proper antiviral research to 514 
be conducted. 515 
HEV is an extremely interesting pathogen that deserves more profound study. In the last decade, 516 
much effort has gone to the HCV antiviral field. As many (candidate) drugs are currently in advanced 517 
clinical development, awaiting market approval or even on the market, HEV research could 518 
potentially benefit from research groups switching their main focus from HCV to HEV. 519 
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FIGURE LEGENDS 1073 
Figure 1 – Organization of the HEV genome: Non-structural proteins are translated from ORF1 while 1074 
the ORF2 and ORF3 structural proteins are translated from a single subgenomic RNA. UTR, 1075 
untranslated region; Y, Y-domain; PCP, papain-like cysteine protease; HVR, hypervariable region; X, 1076 
macro domain; RdRp, RNA-dependent RNA polymerase. 1077 
Figure 2 – HEV replication cycle: HEV particles first bind to heparan sulphate proteoglycans (HSPG) 1078 
and are consequently transferred to an unknown functional receptor, thus mediating cellular uptake 1079 
through clathrin-mediated endocytosis. Following uncoating, the viral RNA genome is released into 1080 
the cytoplasm and translated into non-structural proteins. These proteins form a replication complex 1081 
that produces new full-length and subgenomic viral RNA. The latter is translated into capsid protein 1082 
(ORF2) and the membrane associated ORF3 protein that is known to interfere with interferon-α 1083 
signaling. Viral RNA is packaged into capsid protein and released from the cell with help of the host 1084 
factor Tumor susceptibility gene 101 (Tsg101). The released particles are associated with lipids and 1085 
ORF3 proteins; both are consequently removed through the bile acids and digestive proteases 1086 
respectively. 1087 
Figure 3 – HEV species and genotypes: The phylogenetic relationship of different human HEV 1088 
genotypes and the reported animal strains was plotted with the Virus Pathogen Database and 1089 
Analysis Resource (ViPR, (Pickett et al., 2012)) based on following sequences: HEV gt1 (GenBank 1090 
accession no. M80581), HEV gt2 (M74506), HEV gt3 (HQ389543), rabbit HEV (FJ906895), HEV gt4 1091 
(AB220973), wild boar HEV 2006 (AB602441), wild boar HEV 2009 (AB573435), ferret HEV 1092 
(JN998606), rat HEV (GU345043), bat HEV (JQ001749), avian HEV (AY535004), CTV (HQ731075). CTV, 1093 
cutthroat trout virus; gt, genotype. 1094 
Figure 4 – Geographic distribution of HEV genotypes 1-4: Countries with confirmed human 1095 
infections are color-coded according to the detected genotype. This is probably an incomplete 1096 
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picture as there are no data available for many countries and genotyping is not always performed 1097 
and/or reported. 1098 
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Genotypes 
Animal model Virus species Characteristics References 
Chicken Avian HEV Seroconversion, virus shedding, gross hepatic lesions, 
splenomegaly 
(Billam et al., 2005) 
Trout Cutthroat trout virus Avirulent, only detected during spawning, IFN induction (Hedrick et al., 1994) 
Pig HEV gt 3 and 4 Seroconversion, virus shedding, histopathological damage (Feagins et al., 2008; Halbur et al., 
2001; Sanford et al., 2011) 
Macaque (rhesus, 
cynomolgus), 
chimpanzee 
HEV gt 1-4 Seroconversion, virus shedding, histopathological damage (Emerson et al., 2001; Meng et 
al., 1998; Purcell et al., 2003; Yu 
et al., 2010) 
Rat        (Wistar) Rat HEV Seroconversion, virus shedding, no alterations in ALT (Li et al., 2013b) 
 HEV gt 1, 3 or 4 Not infectable (Li et al., 2013b) 
              (Nude) Rat HEV Seroconversion, limited virus shedding, higher titers than 
in immunecompetent rats 
(Li et al., 2013b; Purcell et al., 
2011) 
 HEV gt 3 Not infectable (Li et al., 2013a) 
              (Sprague-Dawley) Rat HEV Seroconversion, limited virus shedding, histopathological 
damage, no alterations in ALT 
(Purcell et al., 2011) 
 HEV gt 1, 2 or 3 Not infectable (after intravenous injection) (Purcell et al., 2011) 
 HEV gt 4 Seroconversion, virus shedding (after intrahepatic RNA 
inoculation) 
(Zhu et al., 2013) 
Mouse  (Balb/c nude) HEV gt 4 Seroconversion, virus shedding, histopathological liver 
damage 
(Huang et al., 2009) 
              (C57BL/6) HEV gt 1, 3 and 4 Not infectable (Li et al., 2008) 
Rabbit Rabbit HEV Seroconversion, virus shedding (Cheng et al., 2012) 
 HEV gt 4 Seroconversion, virus shedding, symptomatic hepatitis 
(only for H4-NJ703 strain) 
(Cheng et al., 2012) 
Mongolian gerbil HEV gt 4 Virus shedding, slight histopathological liver changes (Li et al., 2009) 
Table 1 – Overview of reported animal models for HEV and surrogate viruses with reported pathology (gt, genotype; IFN, interferon; ALT, alanine 
transaminase) 
HEV-encoded proteins Confirmed functions Crystral 
structure? 
References 
ORF1 Non-structural proteins   
Methyltransferase Guanyltransferase, guanine-7-methyltransferase No (Magden et al., 2001) 
Papain-like cystein 
protease 
Proteolytic processing of ORF1? Deubiquitinating activity No (Karpe and Lole, 2011; Parvez, 
2013; Perttilä et al., 2013; Sehgal 
et al., 2006) 
Hypervariable region Influences efficiency of viral RNA replication, host/cell type specificity? No (Pudupakam et al., 2011; Shukla 
et al., 2012) 
Macrodomain Poly-ADP-ribose-binding, weak ADP-ribose 1”-phosphohydrolase activity No (Egloff et al., 2006) 
Helicase 5’-3’ RNA unwinding, NTPase, RNA 5’-triphosphatase No (Karpe and Lole, 2010a, 2010b) 
RdRp RNA-dependent RNA polymerase activity No (Agrawal et al., 2001; Rehman et 
al., 2008) 
 
ORF2 Capsid protein Yes (HEV-like 
particle) 
(Guu et al., 2009; Yamashita et 
al., 2009) 
 
ORF3 Interaction with multiple cellular proteins, including Tsg101, 
hemopexin,… 
Suppression of interferon-α signaling 
Particle egress 
No (Geng et al., 2013; Ratra et al., 
2008; Surjit et al., 2006)  
(Dong et al., 2012)  
(Yamada et al., 2009) 
Table 2 – HEV-encoded proteins and their (putative) functions 
